Detalhe da pesquisa
1.
Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
Circulation
; 149(5): 343-353, 2024 01 30.
Artigo
Inglês
| MEDLINE | ID: mdl-37860863
2.
Evinacumab Reduces Triglyceride-Rich Lipoproteins in Patients with Hyperlipidemia: A Post-Hoc Analysis of Three Randomized Clinical Trials.
Cardiovasc Drugs Ther
; 2024 Mar 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38446275
3.
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
Eur Heart J
; 2023 Mar 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36879424
4.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Circulation
; 146(9): 657-672, 2022 08 30.
Artigo
Inglês
| MEDLINE | ID: mdl-35770629
5.
Evinacumab in Patients with Refractory Hypercholesterolemia.
N Engl J Med
; 383(24): 2307-2319, 2020 12 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33196153
6.
Evinacumab for Homozygous Familial Hypercholesterolemia.
N Engl J Med
; 383(8): 711-720, 2020 08 20.
Artigo
Inglês
| MEDLINE | ID: mdl-32813947
7.
Effect of alirocumab on cataracts in patients with acute coronary syndromes.
BMC Ophthalmol
; 23(1): 279, 2023 Jun 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37328736
8.
Alirocumab after acute coronary syndrome in patients with a history of heart failure.
Eur Heart J
; 43(16): 1554-1565, 2022 04 19.
Artigo
Inglês
| MEDLINE | ID: mdl-34922353
9.
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Circulation
; 143(11): 1109-1122, 2021 03 16.
Artigo
Inglês
| MEDLINE | ID: mdl-33438437
10.
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Circulation
; 141(20): 1608-1617, 2020 05 19.
Artigo
Inglês
| MEDLINE | ID: mdl-32223446
11.
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
Circulation
; 141(8): 624-636, 2020 02 25.
Artigo
Inglês
| MEDLINE | ID: mdl-31707832
12.
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
N Engl J Med
; 379(22): 2097-2107, 2018 11 29.
Artigo
Inglês
| MEDLINE | ID: mdl-30403574
13.
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
Eur Heart J
; 41(42): 4114-4123, 2020 11 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32820320
14.
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Eur Heart J
; 41(44): 4245-4255, 2020 11 21.
Artigo
Inglês
| MEDLINE | ID: mdl-33051646
15.
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
Eur Heart J
; 41(24): 2248-2258, 2020 06 21.
Artigo
Inglês
| MEDLINE | ID: mdl-31732742
16.
Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.
Circulation
; 140(6): 470-486, 2019 08 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31242752
17.
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.
Circulation
; 140(25): 2054-2062, 2019 12 17.
Artigo
Inglês
| MEDLINE | ID: mdl-31707788
18.
Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Circulation
; 140(2): 103-112, 2019 07 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31117810
19.
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
N Engl J Med
; 377(3): 211-221, 2017 07 20.
Artigo
Inglês
| MEDLINE | ID: mdl-28538136
20.
Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.
Arterioscler Thromb Vasc Biol
; 39(11): 2248-2260, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31578082